Wednesday, March 20, 2019 10:19:05 AM
I beg to differ.
BLOZF has been targeting THC compounds....PERIOD. By refining, refining and more refining the process...BLOZF has become closer and closer to the finish line.
BTHCF keeps changing the direction of target breath compounds.....EACH time BTHCF changes breath target compounds...we go back to square one. Each time BTHCF goes back to square one, while BLOZF keeps refining its breathalyzer....the valuation between the two companies widens...as expected by most people. So...Its simply unreasonable to believe otherwise.
I agree...both markets are immense. If BTHCF could maintain direction and focus with the breathalyzer development...we could tap that market.
All things are NOT equal.....BLOZF is in manufacturing and field testing....and therefore...very close to the finish line........meanwhile BTHCF keeps starting over with breath target compounds.
The ALGERNON story is a poor substitute for a breathalyzer. I think targeting big Pharma to partner with medical breathalyzer development...would be a story worth hearing...and investing in...and bring back the pothead investors, and also the non pothead investors.
GLTA
GO FOR THE BREATHALYZER ALGERNON...GO BLOZF...LIHT THE WAY
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM